Galmed Pharmaceuticals Ltd. diskutieren
Galmed Pharmaceuticals Ltd.
WKN: A1XFUX / Symbol: GMED / Name: Galmed Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
6,40 €
4,84 %
Globus Medical (NYSE:GMED) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) had its price target raised by analysts at Royal Bank Of Canada from $92.00 to $100.00. They now have an "outperform" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (NYSE:GMED) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its price target raised by Needham & Company LLC from $112.00 to $114.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its price target raised by Barclays PLC from $118.00 to $123.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its price target raised by Wells Fargo & Company from $98.00 to $104.00. They now have an "overweight" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its price target raised by Needham & Company LLC from $114.00 to $117.00. They now have a "buy" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its price target raised by Royal Bank Of Canada from $115.00 to $120.00. They now have an "outperform" rating on the stock.
Ratings data for GMED provided by MarketBeat
Globus Medical (GMED) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for GMED provided by MarketBeat
Neueste Beiträge
Scotiabank in Sailpoint Technologies Holdings diskutieren